Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2025 | What is on the horizon for the treatment of B-cell and T-cell ALL?

Nicholas Short • 6 Dec 2025
ASH 2025
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab CAR-T Obecabtagene autoleucel

Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the exciting developments in the treatment of acute lymphoblastic leukemia (ALL). Dr Short highlights potential therapeutic strategies on the horizon for both B-cell and T-cell ALL. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nicholas Short

Azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML: long-term follow-up
2:31
Azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML: long-term follow-up
Nicholas Short • 6 Dec 2025
Predictors of outcomes with and without alloSCT after first salvage therapy for R/R B-ALL
2:17
Predictors of outcomes with and without alloSCT after first salvage therapy for R/R B-ALL
Nicholas Short • 6 Dec 2025
Comparing PCR for BCR::ABL1 versus NGS-based MRD in Ph+ ALL: which method is superior?
2:20
Comparing PCR for BCR::ABL1 versus NGS-based MRD in Ph+ ALL: which method is superior?
Nicholas Short • 6 Dec 2025
The current role of MRD in ALL subtypes
2:12
The current role of MRD in ALL subtypes
Nicholas Short • 3 Sep 2025

Related Videos

Guidance for treating patients with CLL who have relapsed after initial therapy
2:47
Guidance for treating patients with CLL who have relapsed after initial therapy
Nicholas Short • 7 Dec 2025
Azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML: long-term follow-up
2:31
Azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML: long-term follow-up
Nicholas Short • 6 Dec 2025
Predicting and preventing therapy-related myeloid neoplasms
3:30
Predicting and preventing therapy-related myeloid neoplasms
Nicholas Short • 7 Dec 2025
Advice for applying the Clonal Hematopoiesis Risk Score in clinical practice
1:46
Advice for applying the Clonal Hematopoiesis Risk Score in clinical practice
Nicholas Short • 16 Dec 2025
The content of VJHemOnc is intended for healthcare professionals